Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

BMC Infectious Diseases
Thomas W L ScheerenKamal Hamed

Abstract

Patients with pneumonia who are elderly or severely ill are at a particularly high risk of mortality. This post hoc retrospective analysis of data from two Phase III studies evaluated early improvement outcomes in subgroups of high-risk patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia [VAP]). One study included hospitalised CAP patients randomised to ceftobiprole or ceftriaxone ± linezolid treatment. The other study included HAP patients, who were randomised to ceftobiprole or ceftazidime plus linezolid treatment. The primary outcome was rate of early clinical response (Day 3 in CAP and Day 4 in HAP patients). Additional outcome measures included clinical cure at a test-of-cure visit, 30-day all-cause mortality and safety. The overall high-risk group comprised 398 CAP patients and 307 HAP patients with risk factors present at baseline. The rate of early response was numerically higher in ceftobiprole-treated patients vs comparator-treated patients in the following high-risk groups: CAP patients aged ≥75 years (16.3% difference, 95% confidence interval [CI]: 1.8, 30.8); CAP patients with COPD (20.1% difference, 95% CI: 8.8, 31.1); all high-risk HAP p...Continue Reading

References

Jan 23, 1997·The New England Journal of Medicine·M J FineW N Kapoor
Dec 12, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·B A Cunha
Sep 3, 2002·American Journal of Respiratory and Critical Care Medicine·Derek C AngusWishwa N Kapoor
Sep 19, 2003·Intensive Care Medicine·Jordi VallésJordi Rello
Dec 8, 2005·JAMA : the Journal of the American Medical Association·Alicia M FryLarry J Anderson
Oct 24, 2008·Respiratory Medicine·David M ManninoVictor A Kiri
Nov 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Drahomir Aujesky, Michael J Fine
Jan 15, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Adamantia LiapikouAntoni Torres
Feb 24, 2010·Archives of Internal Medicine·Michael R EberAnup Malani
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lena M Napolitano
Jul 10, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Raul E IsturizJulio Ramirez
Jan 1, 2009·Aging Health·John E StupkaMarcos I Restrepo
Feb 18, 2011·Critical Care : the Official Journal of the Critical Care Forum·Mònica MagretUNKNOWN EU-VAP/CAP Study Group
Mar 27, 2012·The Journal of Infectious Diseases·Peter C WroeSusan S Huang
Aug 17, 2012·Critical Care : the Official Journal of the Critical Care Forum·Nicolas MongardonJean-Paul Mira
Apr 23, 2013·Applied Health Economics and Health Policy·Reiko SatoBrett Pinsky
Apr 12, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Samir S AwadMarc Engelhardt
Nov 18, 2015·Future Microbiology·Thomas W L Scheeren
Dec 17, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George H TalbotUNKNOWN Biomarkers Consortium of the Foundation for the National Institutes of Health CABP-ABSSSI and HABP-VABP Project Teams
May 15, 2016·BMC Health Services Research·Derek WeyckerStephen I Pelton
Mar 11, 2017·Human Vaccines & Immunotherapeutics·Filiz KosarCaglar Cuhadaroglu
May 1, 2016·BJA Education·A J Morgan, A J Glossop

❮ Previous
Next ❯

Citations

Sep 26, 2019·Expert Review of Anti-infective Therapy·Daniele Roberto GiacobbeMatteo Bassetti
Feb 12, 2021·Antibiotics·Tommaso LupiaFrancesco Giuseppe De Rosa
May 25, 2021·Journal of Global Antimicrobial Resistance·A OlivaC M Mastroianni

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00326287
NCT00210964
NCT00229008

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.